Prostaglandin E2 induces growth inhibition, apoptosis and differentiation in T and B cell-derived acute lymphoblastic leukemia cell lines (CCRF-CEM and Nalm-6)

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 87, Issue 1, 2012, Pages 17-24

  Fard, Shahrzad Soleymani ^a   Tehrani, Mahmood Jeddi ^a   Ardekani, Ali M ^a  

^a AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Acute lymphoblastic leukemia; Apoptosis; Differentiation; Flow cytometry; Prostaglandin E2

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CASPASE 3; CD19 ANTIGEN; CD38 ANTIGEN; CD7 ANTIGEN; PROSTAGLANDIN E2; TETRAZOLIUM; TRICHOSTATIN A;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CELL CULTURE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; T LYMPHOCYTE; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AZACITIDINE; CASPASE 3; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DINOPROSTONE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84864113055     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2012.04.012     Document Type: Article

References (66)

1. Cheok M.H., Evans W.E. Acute lymphoblastic leukemia: a model for the pharmacogenomics of cancer therapy. Cancer 2006, 6:117-129.
2. Estey E. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000, 14:476-479.
3. Miller W.H., Waxman S. Differentiation induction as a treatment for hematologic malignancies. Oncogene 2002, 21:3496-3506.
4. Abujamra A.L., Pinheiro dos Santos M., Roesler R., Schwartsmann G., Lunardi Brunetto A. Histone deacetylase inhibitors: a new perspective for the treatment of leukemia. Leuk. Res. 2010, 34:687-695.
5. Chen Y.-C., Shen S.-C., Tsai S.-H. Prostaglandin D2 and J2 induce apoptosis in human leukemia cells via activation of the caspase 3 cascade and production of reactive oxygen species. Biochim. Biophys. Acta 2005, 1743:291-304.
6. Takadera T., Shiraishi Y., Ohyashiki T. Prostaglandin E2 induced caspase-dependent apoptosis possibly through activation of EP2 receptors in cultured hippocampal neurons. Neurochem. Int. 2004, 45:713-719.
7. Ackerman R.C., Murdoch W.J. Prostaglandin-induced apoptosis of ovarian surface epithelial cells. Prostaglandins 1993, 45:475-485.
8. Grichenko O.E., Shaposhnikova V.V., Kudryavtsev A.A., Korystov Yu N. Apoptosis in P388 leukemia cells induced by specific inhibitors of 5- and 12-lipoxygenase and the product of cyclooxygenase, prostaglandin E2. Biol. Bull. 2004, 31(3):221-225.
9. Smith S.J., Green L.M., Hayes M.E., Mawer E.B. Prostaglandin E2 regulates vitamin D receptor expression, vitamin D24-hydroxylase activity and cell proliferation in an adherent human myeloid leukemia cell line (Ad-HL60). Prostaglandins other Lipid Mediators 1999, 57:73-85.
10. Oki Y., Issa J.P. Review: recent clinical trials in epigenetic therapy. Rev. Recent Clin. Trials 2006, 1(2):169-182.
11. Garea-Villar A., Steller M. Histone deacetylase inhibitors: understanding a new wave of anti-cancer agents. Int. J. Cancer 2004, 112:171-178.
12. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms o f cell death and promise in combination cancer therapy. Cancer Lett. 2008, 269(1):7-17.
13. Yoshida M., Matsuyama A., Komatsu Y., Nishino N. From discovery to the coming generation of histone deacetylase inhibitors. Curr. Med. Chem. 2003, 22:2351-2358.
14. Park H., Lee Y.J., Kim T.H., Lee J., Yoon S., Chol W.S., et al. Effects of trichostatin A, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells. Int. J. Mol. Med. 2008, 22:605-611.
15. Bradbury C.A., Khanim F.L., Hayden R., Bunce C.M., White D.A., Drayson M.T., et al. Histone deacetylases in acute myeloid leukemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005, 19:1751-1759.
16. Jones P.A., Taka i D. The role of DNA methylation in mammalian epigenetics. Science 2001, 293(10):68-70.
17. Zhu W.G., Otterson G.A. The interaction of histone deacetylase inhibitor and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem. Anti-Cancer Agents 2003, 3:187-199.
18. Lubbert M.D.N.A. Methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobin opathies: clinical results and possible mechanisms of action. Curr. Top. Microbiol. Immunol. 2000, 249:135-164.
19. Wijermans P., Lubbert M., Verhoe f G., et al. Low-dose 5-aza-2deoxycytidine, a DNA hypomethylating agent, for the treatment of high risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 2000, 18:956-962.
20. Lyons J., Bayar E., Fine G., et al. Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies. Curr. Opinion Invest. Drugs 2003, 4:1442-1450.
21. Issa J.P., Garcia-Manero G., Giles F.J., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103:1635-1640.
22. Faderl S., Lotan R., Kantarjian H.P., Harris D., Van Q., Estrov Z.N. (4 Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). Leuk. Res. 2003, 27:259-266.
23. Das A., Banik N.L., Ray S.K. Retinoids induced astrocytic differentiation with down regulation of telomerase activity and enhanced sensitivity to taxol for apoptosis in human glioblastoma T98G and U87MG cells. J. Neurooncol. 2008, 87:9-22.
24. Wagner K.D., Wagner N., Sukhatme V.P., Scholz H. Activation of vitamin D receptor by the Wilms' tumor gene product mediates apoptosis of renal cells. J. Am. Soc. Nephrol. 2001, 12:1188-1196.
25. Matsui W., Smith B.D., Vala M., Beal N., Huff C.A., Diehl L.F., et al. Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukemia. Br. J. Haematol. 2005, 128:853-862.
26. Matsui W.H., Gladstone D.E., Vala M.S., Barber J.P., Brodsky R.A., Smith B.D., et al. The role of growth factors in the activity of pharmacological differentiation agents. Cell Growth Differ. 2002, 13:275-283.
27. Leszczyniecka M., Roberts T., Dent P., Grant S., Fisher P.B. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol. Ther. 2001, 90:105-156.
28. Hotfilder M., Rottgers S., Rosemann A., Jurgens H., Harbott J., Vormoor J. Immature CD34+CD19 progenitor/stem cells in TEL/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal. Blood 2002, 100:640-646.
29. Castor A., Nilsson L., Astrand-Grundstrom I., Buitenhuis M., Ramirez C., Anderson K., et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat. Med. 2005, 11:630-637.
30. Hotfilder M., Rottgers S., Rosemann A., Schrauder A., Schrappe M., Pieters R., et al. Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19 cells. Cancer Res. 2005, 65:1442-1449.
31. Sato S., Miller A.S., Howard M.C., Tedder T.F. Regulation of B lymphocyte development and activation by the CD19/CD21/ CD81/Leu 13 complex requires the cytoplasmic domain of CD19. J. Immunol. 1997, 159:3278-3287.
32. Fujimoto M., Poe J.C., Hasegawa M., Tedder T.F. CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification. Immunol. Res. 2000, 22:281-298.
33. Donis-Hernandez F.R., Parkhouse R.M., Santos-Argumedo L. Ontogeny, distribution and function of CD38-expressing B lymphocytes in mice. Eur. J. Immunol. 2001, 31:1261-1267.
34. Lin T.L., Vala M.S., Barber J.P., Karp J.E., Smith B.D., Matsui W., et al. Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia 2007, 21:1915-1920.
35. Joo Woo H., Lee S.J., Choi B.T., Park Y.-M., Choi Y.H. Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells. Exp. Mol. Pathol. 2007, 82:77-84.
36. Petrella A., D'Acunto C.W., Rodriquez M., Festa M., Tosco A., Bruno I., et al. Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukemia cell lines: role of annexin A1. Eur. J. Cancer 2008, 44(5):740-749.
37. Scuto A., Kirschbaum M., Kowolik C., Kretzner L., Juhasz A., Atadja P., et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood 2008, 111(10):5093-5100.
38. Savickiene J., Borutinskaite V.-V., Treigyte G., Magnusson K.-E., Navakauskiene R. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. Eur. J. Pharmacol. 2006, 549:9-18.
39. Yao J., Duan L., Fan M., Wu X. NF-κB signaling pathway is involved in growth inhibition, G2/M arrest and apoptosis induced by trichostatin A in human tongue carcinoma cells. Pharmacol. Res. 2006, 54:406-413.
40. Platta C.S., Greenblatt D.Y., Kunnimalaiyaan M., Chen H. The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J. Surg. Res. 2007, 142:219-226.
41. Giles F., Fischer T., Cortes J., Garcia-Manero G., Beck J., Ravandi F., et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. 2006, 12(15):4628-4635.
42. Gojo I., Jiemjit A., Trepel J.B., Sparreboom A., Figg W.D., Rollins S., et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007, 109(7):2781-2790.
43. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111(3):1060-1066.
44. Kuendgen A., Schmid M., Schlenk R., Knapp S., Hildebrandt B., Steidl C., et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006, 106(1):112-119.
45. Limonta M., Colombo T., Damia G., Catapano C.V., Conter V., Gervasoni M., et al. Cytotoxic activity and mechanism of action of 5-aza-2-deoxycytidine in human CML cells. Leuk. Res. 1993, 17(11):977-982.
46. Momparler R.L., Bouchard J., Onetto N., Rivard G.F. 5-Aza-2-deoxycytidine therapy in patients with acute leukemia inhibits and methylation. Leuk. Res. 1984, 8(2):181-185.
47. Rivard G.E., Momparler R.L., Demers J., Benoit P., Raymond R., Lin K., et al. Phase I study on 5-aza-2-deoxycytidine in children with acute leukemia. Leuk. Res. 1981, 6:453-462.
48. Raynal N., Momparler L.F., Rivard G.E., Momparler R.L. 3-Deazauridine enhances the antileukemic action of 5-aza-2-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase. Leuk. Res. 2011, 35(1):110-118.
49. Wang D., DuBois R.N. Prostaglandins and cancer. Gut 2006, 55:115-122.
50. Koren R., Ravid A., Rotem C., Shohami E., Liberman U.A., Novogrodsky A. 1,25-Dihydroxyvitamin D enhances prostaglandin E production by monocytes. (A mechanism which partially accounts for the antiproliferative effect of 1,25(OH),D on lymphocytes). FEBS Lett. 1986, 205(1):113-116.
51. Studzinski G.P., Harrison L.E. Differentiation-related changes in the cell cycle traverse. Int. Rev. Cytol. 1999, 189:1-58.
52. Levva A., Schwartsmann G., Boeije L., Pinedo H.M., Waal F. Growth inhibitory effects of 5-aza-2-deoxycytidine in HL-60 promelocytic leukemia cells resistant to differentiation induction. Biochem. Biophys. Res. Commun. 1986, 141(2):629-635.
53. Jing H., Hongli L., Yan C. Effects of trichostatin A on HDAC8 expression, proliferation and cell cycle of Molt-4 cells. J. Huazhong Univ. Sci. Technol. 2006, 26(5):531-533.
54. Nishioka C., Ikezoe T., Yang J., Komatsu N., Bandobashi K., Taniguchi A., et al. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor KB. Leuk. Res. 2008, 32:287-296.
55. Ga'lfi P., Neogra'dy Z., Csorda's A. Apoptosis sensitivity is not correlated with sensitivity to proliferation inhibition by the histone deacetylase inhibitors butyrate and TSA. Cancer Lett. 2002, 188:141-152.
56. Schneider-Stock R., Diab-Assef M., Astrid R., Foltzer-Jourdainne C., Carsten B., Roland H., et al. 5-AZA-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms. J. Pharmacol. Exp. Ther. 2005, 312(2):525-536.
57. His L.C., Xi X., Wu Y.G., Lippman S.M. The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Mol. Cancer Ther. 2005, 4(11):1740-1746.
58. Cho S.-J., Kim N., Kim J.S., Jung H.C., Song I.S. The anti-cancer effect of COX-2 inhibitors on gastric cancer cells. Dig. Dis. Sci. 2007, 52(7):1713-1721.
59. His L.C., Xi X., Wu Y., Lippman S.M. The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Mol. Cancer Ther. 2005, 4:1740.
60. Soleymanifard S.H., Jeddi-Tehrani M., Akhondi M.M., Hashemi M., Ardekani A. Flow cytometric analysis of 4-HPR-induced apoptosis and cell cycle arrest in acute myelocytic leukemia cell line (NB-4). Avicenna J. Med. Biotechnol. 2010, 2(1):53-61.
61. 3 induce growth inhibition, apoptosis and differentiation in T and B cell-derived acute lymphoblastic leukemia cell lines (CCRF-CEM and Nalm-6). Avicenna J. Med. Biotechnol. 2011, 3(4):177-193.
62. Cox C.V., Evely R.S., Oakhill A., Pamphilon D.H., Goulden N.J., Blair A. Characterization of acute lymphoblastic leukemia progenitor cells. Blood 2004, 104:2919-2925.
63. Campana D., Behm F.G. Immunophenotyping of leukemia. J. Immunol. Methods 2000, 243:59-75.
64. Lewis R.E., Cruse J.M., Sanders C.M., Webb R.N., Tillman B.F., et al. The immunophenotype of pre-TALL/LBL revisited. Exp. Mol. Pathol. 2006, 81:162-165.
65. Popov A.M., TIu Verzhbitskaia, Tsaur G.A., Shorikov E.V., Savel'ev L.I., Tsvirenko S.V., et al. Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia. Klin. Lab. Diagn. 2010, 8:36-41.
66. Babusikova O., Stevulova L., Fajtova M. Immunophenotyping parameters as prognostic factors in T-acute leukemia patients. Neoplasma 2009, 56(6):508-513.